This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-142-3p | CDC6 | -1.42 | 0 | 3.43 | 0 | miRNAWalker2 validate | -0.21 | 0.0024 | NA | |
2 | hsa-miR-193b-3p | CDC6 | -0.17 | 0.27202 | 3.43 | 0 | miRNAWalker2 validate | -0.18 | 0.04519 | NA | |
3 | hsa-miR-199a-5p | CDC6 | -1.99 | 0 | 3.43 | 0 | miRanda | -0.27 | 0 | NA | |
4 | hsa-miR-26a-5p | CDC6 | -0.96 | 0 | 3.43 | 0 | miRNAWalker2 validate | -0.79 | 0 | 25100863; 27158389 | Here it is demonstrated that miR26a and miR26b inhibit replication licensing and the proliferation migration and invasion of lung cancer cells by targeting CDC6; The current study suggests that miR26a miR26b and CDC6 and factors regulating their expression represent potential cancer diagnostic and prognostic markers as well as anticancer targets;miR 26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression; Bioinformatics analysis revealed Cdc6 was a target gene of miR-26a; dual-luciferase assay and validation assay showed miR-26a could act on the 3'UTR of Cdc6 to regulate Cdc6 expression; These findings suggest that miR-26a may act on the 3'UTR of Cdc6 to regulate Cdc6 expression which then inhibit the proliferation of ovarian cancer cells and induce their apoptosis |
5 | hsa-miR-3607-3p | CDC6 | -2.16 | 0 | 3.43 | 0 | mirMAP | -0.42 | 0 | NA | |
6 | hsa-miR-101-3p | CDC7 | -1.48 | 0 | 2.02 | 0 | miRNAWalker2 validate | -0.62 | 0 | NA | |
7 | hsa-miR-126-5p | CDC7 | -0.43 | 7.0E-5 | 2.02 | 0 | mirMAP | -0.39 | 1.0E-5 | NA | |
8 | hsa-miR-192-5p | CDC7 | -0.5 | 0.00345 | 2.02 | 0 | miRNAWalker2 validate | -0.2 | 0.00036 | NA | |
9 | hsa-miR-199a-5p | CDC7 | -1.99 | 0 | 2.02 | 0 | MirTarget; miRanda | -0.11 | 0.00038 | NA | |
10 | hsa-miR-215-5p | CDC7 | -0.98 | 3.0E-5 | 2.02 | 0 | miRNAWalker2 validate | -0.11 | 0.00749 | NA | |
11 | hsa-miR-3065-3p | CDC7 | -1.04 | 5.0E-5 | 2.02 | 0 | MirTarget | -0.13 | 0.00068 | NA | |
12 | hsa-miR-335-5p | CDC7 | -1.61 | 0 | 2.02 | 0 | MirTarget | -0.18 | 0.00032 | NA | |
13 | hsa-miR-3607-3p | CDC7 | -2.16 | 0 | 2.02 | 0 | miRNATAP | -0.28 | 0 | NA | |
14 | hsa-miR-455-5p | CDC7 | -0.27 | 0.05813 | 2.02 | 0 | miRanda | -0.14 | 0.03623 | NA | |
15 | hsa-miR-195-3p | DBF4 | -1.09 | 0 | 0.92 | 0 | mirMAP | -0.12 | 8.0E-5 | NA | |
16 | hsa-miR-30a-5p | DBF4 | -0.63 | 0.00011 | 0.92 | 0 | MirTarget | -0.23 | 0 | NA | |
17 | hsa-miR-30b-5p | DBF4 | -0.54 | 2.0E-5 | 0.92 | 0 | MirTarget | -0.12 | 0.0115 | NA | |
18 | hsa-miR-30e-5p | DBF4 | -0.63 | 0 | 0.92 | 0 | MirTarget | -0.17 | 0.00391 | NA | |
19 | hsa-miR-3607-3p | DBF4 | -2.16 | 0 | 0.92 | 0 | MirTarget; miRNATAP | -0.16 | 0 | NA | |
20 | hsa-miR-542-3p | DBF4 | -1.31 | 0 | 0.92 | 0 | miRanda | -0.13 | 0.00125 | NA | |
21 | hsa-miR-126-5p | MCM10 | -0.43 | 7.0E-5 | 3.45 | 0 | mirMAP | -0.82 | 0 | NA | |
22 | hsa-miR-192-5p | MCM10 | -0.5 | 0.00345 | 3.45 | 0 | miRNAWalker2 validate | -0.21 | 0.01514 | NA | |
23 | hsa-miR-199a-5p | MCM10 | -1.99 | 0 | 3.45 | 0 | miRanda | -0.26 | 0 | NA | |
24 | hsa-miR-215-5p | MCM10 | -0.98 | 3.0E-5 | 3.45 | 0 | miRNAWalker2 validate | -0.16 | 0.0102 | NA | |
25 | hsa-miR-326 | MCM10 | -1.88 | 0 | 3.45 | 0 | miRanda | -0.25 | 0.0003 | NA | |
26 | hsa-miR-139-5p | MCM2 | -2.11 | 0 | 2.39 | 0 | miRanda | -0.6 | 0 | NA | |
27 | hsa-miR-192-5p | MCM3 | -0.5 | 0.00345 | 1.38 | 0 | miRNAWalker2 validate | -0.12 | 0.00283 | NA | |
28 | hsa-miR-193b-3p | MCM3 | -0.17 | 0.27202 | 1.38 | 0 | miRNAWalker2 validate | -0.11 | 0.015 | NA | |
29 | hsa-miR-26b-5p | MCM3 | -1.11 | 0 | 1.38 | 0 | miRNAWalker2 validate | -0.34 | 0 | NA | |
30 | hsa-miR-450b-5p | MCM3 | -1.34 | 0 | 1.38 | 0 | miRNATAP | -0.22 | 0 | NA | |
31 | hsa-let-7b-5p | MCM4 | -0.96 | 0 | 1.33 | 0 | miRNAWalker2 validate | -0.13 | 0.02556 | NA | |
32 | hsa-miR-193b-3p | MCM4 | -0.17 | 0.27202 | 1.33 | 0 | miRNAWalker2 validate | -0.14 | 0.01696 | NA | |
33 | hsa-miR-486-5p | MCM4 | -1.78 | 0 | 1.33 | 0 | miRanda | -0.14 | 0.00013 | NA | |
34 | hsa-miR-542-3p | MCM5 | -1.31 | 0 | 1.34 | 0 | miRanda | -0.28 | 0 | NA | |
35 | hsa-miR-192-5p | MCM6 | -0.5 | 0.00345 | 1.69 | 0 | miRNAWalker2 validate | -0.13 | 0.00416 | NA | |
36 | hsa-miR-30c-1-3p | MCM6 | -1.39 | 0 | 1.69 | 0 | MirTarget | -0.13 | 0.00482 | NA | |
37 | hsa-miR-30c-2-3p | MCM6 | -1.4 | 0 | 1.69 | 0 | MirTarget | -0.27 | 0 | NA | |
38 | hsa-let-7b-5p | MCM7 | -0.96 | 0 | 1.29 | 0 | miRNAWalker2 validate | -0.25 | 0 | NA | |
39 | hsa-miR-99a-5p | MCM8 | -1.51 | 0 | 1.27 | 0 | miRNAWalker2 validate | -0.22 | 0 | NA | |
40 | hsa-miR-24-3p | PCNA | -0.26 | 0.0069 | 0.97 | 0 | miRNAWalker2 validate | -0.17 | 0.00324 | NA | |
41 | hsa-miR-26b-5p | PCNA | -1.11 | 0 | 0.97 | 0 | miRNAWalker2 validate | -0.27 | 0 | NA | |
42 | hsa-miR-30a-5p | PCNA | -0.63 | 0.00011 | 0.97 | 0 | miRNAWalker2 validate | -0.14 | 4.0E-5 | NA | |
43 | hsa-miR-542-3p | PCNA | -1.31 | 0 | 0.97 | 0 | miRanda; miRNATAP | -0.26 | 0 | NA | |
44 | hsa-miR-26b-5p | POLA1 | -1.11 | 0 | 0.83 | 0 | miRNAWalker2 validate | -0.2 | 2.0E-5 | NA | |
45 | hsa-let-7b-5p | POLD2 | -0.96 | 0 | -0.1 | 0.35145 | miRNAWalker2 validate | -0.12 | 0.00017 | NA | |
46 | hsa-miR-107 | POLD3 | 0.24 | 0.01708 | 0.49 | 0 | MirTarget; miRanda | -0.11 | 0.03127 | NA | |
47 | hsa-miR-29a-3p | POLD3 | -0.86 | 0 | 0.49 | 0 | miRNAWalker2 validate | -0.27 | 0 | NA | |
48 | hsa-miR-125a-3p | POLD4 | -0.84 | 4.0E-5 | -0.06 | 0.63158 | miRanda | -0.1 | 0.00092 | NA | |
49 | hsa-miR-335-5p | POLD4 | -1.61 | 0 | -0.06 | 0.63158 | miRNAWalker2 validate | -0.14 | 1.0E-5 | NA | |
50 | hsa-miR-590-5p | POLD4 | -0.1 | 0.31003 | -0.06 | 0.63158 | miRanda | -0.14 | 0.0213 | NA | |
51 | hsa-miR-29a-3p | POLE3 | -0.86 | 0 | 0.2 | 0.00379 | MirTarget | -0.14 | 0 | NA | |
52 | hsa-miR-29c-3p | POLE3 | -1.44 | 0 | 0.2 | 0.00379 | MirTarget | -0.14 | 0 | NA | |
53 | hsa-let-7b-5p | PRIM1 | -0.96 | 0 | 1.3 | 0 | miRNAWalker2 validate | -0.3 | 0 | NA | |
54 | hsa-miR-125a-3p | PRIM1 | -0.84 | 4.0E-5 | 1.3 | 0 | miRanda | -0.13 | 0.00171 | NA | |
55 | hsa-miR-24-3p | PRIM1 | -0.26 | 0.0069 | 1.3 | 0 | miRNAWalker2 validate | -0.26 | 0.00383 | NA | |
56 | hsa-miR-30a-5p | PRIM1 | -0.63 | 0.00011 | 1.3 | 0 | miRNAWalker2 validate | -0.34 | 0 | NA | |
57 | hsa-miR-326 | PRIM2 | -1.88 | 0 | 1.37 | 0 | miRanda | -0.15 | 0 | NA | |
58 | hsa-miR-542-3p | PRIM2 | -1.31 | 0 | 1.37 | 0 | MirTarget; miRanda | -0.28 | 0 | NA | |
59 | hsa-miR-342-3p | RFC1 | -0.32 | 0.04498 | 0.44 | 0 | miRanda | -0.15 | 0 | NA | |
60 | hsa-miR-450b-5p | RFC1 | -1.34 | 0 | 0.44 | 0 | MirTarget; PITA | -0.15 | 0 | NA | |
61 | hsa-let-7a-3p | RFC3 | -0.57 | 0 | 0.96 | 0 | MirTarget | -0.17 | 0.00334 | NA | |
62 | hsa-let-7b-3p | RFC3 | -1.22 | 0 | 0.96 | 0 | MirTarget | -0.18 | 3.0E-5 | NA | |
63 | hsa-let-7f-1-3p | RFC3 | -0.7 | 0 | 0.96 | 0 | MirTarget | -0.15 | 0.00103 | NA | |
64 | hsa-miR-139-5p | RFC3 | -2.11 | 0 | 0.96 | 0 | miRanda | -0.18 | 0 | NA | |
65 | hsa-miR-181c-5p | RFC3 | -0.01 | 0.96913 | 0.96 | 0 | MirTarget | -0.1 | 0.00781 | NA | |
66 | hsa-miR-125b-5p | RFC5 | -1.36 | 0 | 0.43 | 2.0E-5 | MirTarget | -0.18 | 0 | NA | |
67 | hsa-miR-140-5p | RFC5 | -0.22 | 0.01407 | 0.43 | 2.0E-5 | miRanda | -0.12 | 0.03834 | NA | |
68 | hsa-miR-126-5p | RPA1 | -0.43 | 7.0E-5 | 0.1 | 0.17964 | mirMAP | -0.13 | 6.0E-5 | NA | |
69 | hsa-miR-139-5p | RPS27A | -2.11 | 0 | 0.32 | 0.00677 | miRanda | -0.15 | 0 | NA | |
70 | hsa-miR-140-5p | RPS27A | -0.22 | 0.01407 | 0.32 | 0.00677 | miRanda | -0.25 | 0.00014 | NA | |
71 | hsa-miR-26a-5p | RPS27A | -0.96 | 0 | 0.32 | 0.00677 | miRNAWalker2 validate | -0.18 | 0.00111 | NA | |
72 | hsa-miR-30c-5p | RPS27A | -0.43 | 0.00016 | 0.32 | 0.00677 | miRNAWalker2 validate | -0.12 | 0.01923 | NA | |
73 | hsa-miR-139-5p | TOP2A | -2.11 | 0 | 4.15 | 0 | miRanda | -0.96 | 0 | 26079880 | We identified that miR-139 a previous reported anti-metastatic microRNA targets 3'-untranslated region 3'UTR of TOP2a mRNA; Further more we revealed that the forced expression of miR-139 reduces the TOP2a expression at both mRNA and protein levels; And our functional experiments showed that the ectopic expression of miR-139 remarkably inhibits proliferation in luminal type breast cancer cells while exogenous TOP2a expression could rescue inhibition of cell proliferation mediated by miR-139 |
74 | hsa-miR-193b-3p | TOP2A | -0.17 | 0.27202 | 4.15 | 0 | miRNAWalker2 validate | -0.21 | 0.03823 | NA | |
75 | hsa-miR-542-3p | TOP2A | -1.31 | 0 | 4.15 | 0 | miRanda | -0.73 | 0 | NA | |
76 | hsa-let-7c-5p | UBA52 | -1.71 | 0 | 0.28 | 0.01101 | miRNAWalker2 validate | -0.11 | 0.00013 | NA | |
77 | hsa-miR-140-5p | UBA52 | -0.22 | 0.01407 | 0.28 | 0.01101 | miRanda | -0.18 | 0.00278 | NA | |
78 | hsa-miR-542-3p | UBA52 | -1.31 | 0 | 0.28 | 0.01101 | miRanda | -0.12 | 0.00113 | NA | |
79 | hsa-miR-590-3p | UBA52 | -0.47 | 2.0E-5 | 0.28 | 0.01101 | miRanda; mirMAP | -0.2 | 6.0E-5 | NA | |
80 | hsa-miR-148b-5p | UBB | 0.3 | 0.02557 | -0.54 | 0 | miRNAWalker2 validate | -0.1 | 0.00488 | NA | |
81 | hsa-miR-181b-5p | UBB | 0.49 | 0.00105 | -0.54 | 0 | miRNAWalker2 validate | -0.19 | 0 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | DNA REPLICATION | 24 | 208 | 1.862e-45 | 8.665e-42 |
2 | DNA DEPENDENT DNA REPLICATION | 21 | 99 | 1.149e-44 | 2.674e-41 |
3 | DNA METABOLIC PROCESS | 27 | 758 | 2.675e-39 | 4.15e-36 |
4 | CELL CYCLE PHASE TRANSITION | 19 | 255 | 1.04e-30 | 1.21e-27 |
5 | CELL CYCLE G1 S PHASE TRANSITION | 16 | 111 | 3.251e-30 | 2.521e-27 |
6 | G1 S TRANSITION OF MITOTIC CELL CYCLE | 16 | 111 | 3.251e-30 | 2.521e-27 |
7 | DNA REPLICATION INITIATION | 12 | 29 | 1.046e-28 | 6.954e-26 |
8 | NUCLEOTIDE EXCISION REPAIR DNA GAP FILLING | 11 | 24 | 6.3e-27 | 3.664e-24 |
9 | MITOTIC RECOMBINATION | 12 | 41 | 1.579e-26 | 8.163e-24 |
10 | TELOMERE MAINTENANCE VIA RECOMBINATION | 11 | 32 | 3.237e-25 | 1.506e-22 |
11 | CHROMOSOME ORGANIZATION | 22 | 1009 | 1.478e-24 | 5.828e-22 |
12 | DNA DAMAGE RESPONSE DETECTION OF DNA DAMAGE | 11 | 36 | 1.503e-24 | 5.828e-22 |
13 | NUCLEOTIDE EXCISION REPAIR DNA INCISION | 11 | 39 | 4.184e-24 | 1.498e-21 |
14 | TRANSLESION SYNTHESIS | 11 | 41 | 7.875e-24 | 2.617e-21 |
15 | MITOTIC CELL CYCLE | 20 | 766 | 2.499e-23 | 7.753e-21 |
16 | DNA SYNTHESIS INVOLVED IN DNA REPAIR | 12 | 74 | 4.287e-23 | 1.247e-20 |
17 | DNA BIOSYNTHETIC PROCESS | 13 | 121 | 1.4e-22 | 3.832e-20 |
18 | POSTREPLICATION REPAIR | 11 | 54 | 2.363e-22 | 6.109e-20 |
19 | DNA RECOMBINATION | 14 | 215 | 3.184e-21 | 7.797e-19 |
20 | TRANSCRIPTION COUPLED NUCLEOTIDE EXCISION REPAIR | 11 | 73 | 8.664e-21 | 2.016e-18 |
21 | CELL CYCLE PROCESS | 20 | 1081 | 2.366e-20 | 5.241e-18 |
22 | ERROR FREE TRANSLESION SYNTHESIS | 8 | 19 | 2.622e-19 | 5.304e-17 |
23 | ERROR PRONE TRANSLESION SYNTHESIS | 8 | 19 | 2.622e-19 | 5.304e-17 |
24 | TELOMERE ORGANIZATION | 11 | 104 | 5.308e-19 | 1.029e-16 |
25 | CELL CYCLE | 20 | 1316 | 1.149e-18 | 2.138e-16 |
26 | NUCLEOTIDE EXCISION REPAIR | 11 | 113 | 1.374e-18 | 2.46e-16 |
27 | CELLULAR RESPONSE TO DNA DAMAGE STIMULUS | 17 | 720 | 1.435e-18 | 2.473e-16 |
28 | DNA STRAND ELONGATION INVOLVED IN DNA REPLICATION | 8 | 25 | 3.733e-18 | 6.204e-16 |
29 | DNA GEOMETRIC CHANGE | 10 | 81 | 5.327e-18 | 8.547e-16 |
30 | DNA STRAND ELONGATION | 8 | 30 | 2.012e-17 | 3.12e-15 |
31 | NUCLEIC ACID PHOSPHODIESTER BOND HYDROLYSIS | 12 | 254 | 1.993e-16 | 2.991e-14 |
32 | DNA REPAIR | 14 | 480 | 2.63e-16 | 3.824e-14 |
33 | ANATOMICAL STRUCTURE HOMEOSTASIS | 11 | 285 | 4.322e-14 | 6.094e-12 |
34 | CELLULAR RESPONSE TO STRESS | 17 | 1565 | 5.634e-13 | 7.71e-11 |
35 | DNA CONFORMATION CHANGE | 10 | 273 | 1.31e-12 | 1.741e-10 |
36 | DETECTION OF STIMULUS | 11 | 675 | 4.756e-10 | 6.147e-08 |
37 | MISMATCH REPAIR | 5 | 31 | 5.025e-10 | 6.319e-08 |
38 | DNA INTEGRITY CHECKPOINT | 6 | 146 | 3.561e-08 | 4.36e-06 |
39 | NUCLEOTIDE EXCISION REPAIR PREINCISION COMPLEX ASSEMBLY | 4 | 29 | 6.112e-08 | 7.292e-06 |
40 | REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 6 | 162 | 6.618e-08 | 7.698e-06 |
41 | CELL CYCLE CHECKPOINT | 6 | 194 | 1.926e-07 | 2.186e-05 |
42 | MITOTIC DNA INTEGRITY CHECKPOINT | 5 | 100 | 2.09e-07 | 2.315e-05 |
43 | INTERSTRAND CROSS LINK REPAIR | 4 | 44 | 3.445e-07 | 3.728e-05 |
44 | SINGLE ORGANISM BIOSYNTHETIC PROCESS | 11 | 1340 | 5.621e-07 | 5.813e-05 |
45 | HOMEOSTATIC PROCESS | 11 | 1337 | 5.497e-07 | 5.813e-05 |
46 | POSITIVE REGULATION OF CELL CYCLE PROCESS | 6 | 247 | 7.953e-07 | 8.044e-05 |
47 | MITOTIC CELL CYCLE CHECKPOINT | 5 | 139 | 1.077e-06 | 0.0001066 |
48 | REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 5 | 147 | 1.42e-06 | 0.0001376 |
49 | REGULATION OF MITOTIC CELL CYCLE | 7 | 468 | 2.174e-06 | 0.0002064 |
50 | REGULATION OF DNA REPLICATION | 5 | 161 | 2.222e-06 | 0.0002068 |
51 | G1 DNA DAMAGE CHECKPOINT | 4 | 73 | 2.69e-06 | 0.0002454 |
52 | NUCLEOTIDE EXCISION REPAIR DNA DUPLEX UNWINDING | 3 | 22 | 3.322e-06 | 0.0002972 |
53 | REGULATION OF CELL CYCLE PHASE TRANSITION | 6 | 321 | 3.634e-06 | 0.000319 |
54 | NUCLEOTIDE EXCISION REPAIR DNA DAMAGE RECOGNITION | 3 | 23 | 3.816e-06 | 0.0003288 |
55 | POSITIVE REGULATION OF DNA METABOLIC PROCESS | 5 | 185 | 4.39e-06 | 0.0003665 |
56 | POSITIVE REGULATION OF CELL CYCLE | 6 | 332 | 4.411e-06 | 0.0003665 |
57 | GLYCOGEN BIOSYNTHETIC PROCESS | 3 | 25 | 4.947e-06 | 0.0003903 |
58 | POSITIVE REGULATION OF CELL CYCLE ARREST | 4 | 85 | 4.949e-06 | 0.0003903 |
59 | GLUCAN BIOSYNTHETIC PROCESS | 3 | 25 | 4.947e-06 | 0.0003903 |
60 | REGULATION OF DNA METABOLIC PROCESS | 6 | 340 | 5.057e-06 | 0.0003922 |
61 | REGULATION OF NECROTIC CELL DEATH | 3 | 26 | 5.588e-06 | 0.0004262 |
62 | NEGATIVE REGULATION OF MITOTIC CELL CYCLE | 5 | 199 | 6.266e-06 | 0.0004639 |
63 | REGULATION OF TRANSCRIPTION INVOLVED IN G1 S TRANSITION OF MITOTIC CELL CYCLE | 3 | 27 | 6.28e-06 | 0.0004639 |
64 | NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY | 3 | 28 | 7.028e-06 | 0.0005109 |
65 | SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE | 4 | 96 | 8.037e-06 | 0.0005753 |
66 | NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 4 | 98 | 8.724e-06 | 0.0006058 |
67 | MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 30 | 8.694e-06 | 0.0006058 |
68 | MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 32 | 1.06e-05 | 0.0007047 |
69 | GLOBAL GENOME NUCLEOTIDE EXCISION REPAIR | 3 | 32 | 1.06e-05 | 0.0007047 |
70 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO HYPOXIA | 3 | 32 | 1.06e-05 | 0.0007047 |
71 | CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 3 | 33 | 1.165e-05 | 0.0007636 |
72 | PROTEIN DNA COMPLEX SUBUNIT ORGANIZATION | 5 | 229 | 1.238e-05 | 0.0008002 |
73 | REGULATION OF CELL CYCLE ARREST | 4 | 108 | 1.282e-05 | 0.0008174 |
74 | POSITIVE REGULATION OF ERBB SIGNALING PATHWAY | 3 | 36 | 1.521e-05 | 0.0009562 |
75 | VIRION ASSEMBLY | 3 | 37 | 1.653e-05 | 0.001026 |
76 | ERBB2 SIGNALING PATHWAY | 3 | 39 | 1.941e-05 | 0.001188 |
77 | NEGATIVE REGULATION OF TYPE I INTERFERON PRODUCTION | 3 | 40 | 2.097e-05 | 0.001267 |
78 | REGULATION OF DNA DEPENDENT DNA REPLICATION | 3 | 41 | 2.26e-05 | 0.001348 |
79 | POLYSACCHARIDE BIOSYNTHETIC PROCESS | 3 | 42 | 2.432e-05 | 0.001414 |
80 | SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 4 | 127 | 2.43e-05 | 0.001414 |
81 | NEGATIVE REGULATION OF ERBB SIGNALING PATHWAY | 3 | 44 | 2.801e-05 | 0.001609 |
82 | REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 3 | 50 | 4.122e-05 | 0.002339 |
83 | NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 4 | 146 | 4.197e-05 | 0.002353 |
84 | CELLULAR CARBOHYDRATE BIOSYNTHETIC PROCESS | 3 | 51 | 4.376e-05 | 0.002424 |
85 | CELLULAR GLUCAN METABOLIC PROCESS | 3 | 58 | 6.443e-05 | 0.003486 |
86 | GLUCAN METABOLIC PROCESS | 3 | 58 | 6.443e-05 | 0.003486 |
87 | DOUBLE STRAND BREAK REPAIR | 4 | 165 | 6.76e-05 | 0.003615 |
88 | REGULATION OF CELL CYCLE PROCESS | 6 | 558 | 8.245e-05 | 0.004359 |
89 | NEGATIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 3 | 66 | 9.487e-05 | 0.004905 |
90 | NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 3 | 66 | 9.487e-05 | 0.004905 |
91 | REGULATION OF DNA TEMPLATED TRANSCRIPTION IN RESPONSE TO STRESS | 3 | 67 | 9.922e-05 | 0.005074 |
92 | MULTI ORGANISM TRANSPORT | 3 | 68 | 0.0001037 | 0.005189 |
93 | MULTI ORGANISM LOCALIZATION | 3 | 68 | 0.0001037 | 0.005189 |
94 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 9 | 1518 | 0.0001089 | 0.005392 |
95 | I KAPPAB KINASE NF KAPPAB SIGNALING | 3 | 70 | 0.0001131 | 0.005538 |
96 | ENERGY RESERVE METABOLIC PROCESS | 3 | 72 | 0.000123 | 0.005961 |
97 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 6 | 616 | 0.0001419 | 0.006807 |
98 | ANAPHASE PROMOTING COMPLEX DEPENDENT CATABOLIC PROCESS | 3 | 77 | 0.0001502 | 0.007129 |
99 | ERBB SIGNALING PATHWAY | 3 | 79 | 0.000162 | 0.007616 |
100 | POLYSACCHARIDE METABOLIC PROCESS | 3 | 80 | 0.0001682 | 0.007749 |
101 | RECOMBINATIONAL REPAIR | 3 | 80 | 0.0001682 | 0.007749 |
102 | JNK CASCADE | 3 | 82 | 0.000181 | 0.008256 |
103 | REGULATION OF ERBB SIGNALING PATHWAY | 3 | 83 | 0.0001876 | 0.008313 |
104 | NEGATIVE REGULATION OF CELL CYCLE PROCESS | 4 | 214 | 0.0001844 | 0.008313 |
105 | NIK NF KAPPAB SIGNALING | 3 | 83 | 0.0001876 | 0.008313 |
106 | FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 3 | 84 | 0.0001944 | 0.008532 |
107 | TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 85 | 0.0002013 | 0.008754 |
108 | REGULATION OF CELL CYCLE | 7 | 949 | 0.000204 | 0.008788 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | DNA DEPENDENT ATPASE ACTIVITY | 7 | 79 | 9.526e-12 | 8.85e-09 |
2 | DNA HELICASE ACTIVITY | 6 | 53 | 7.334e-11 | 3.406e-08 |
3 | DNA DIRECTED DNA POLYMERASE ACTIVITY | 5 | 28 | 2.915e-10 | 8.137e-08 |
4 | NUCLEOTIDYLTRANSFERASE ACTIVITY | 7 | 131 | 3.504e-10 | 8.137e-08 |
5 | HELICASE ACTIVITY | 7 | 153 | 1.043e-09 | 1.938e-07 |
6 | DNA POLYMERASE ACTIVITY | 5 | 40 | 1.93e-09 | 2.988e-07 |
7 | HYDROLASE ACTIVITY ACTING ON ACID ANHYDRIDES | 11 | 820 | 3.677e-09 | 4.88e-07 |
8 | ATPASE ACTIVITY COUPLED | 7 | 313 | 1.46e-07 | 1.507e-05 |
9 | SINGLE STRANDED DNA BINDING | 5 | 93 | 1.452e-07 | 1.507e-05 |
10 | ADENYL NUCLEOTIDE BINDING | 12 | 1514 | 2.018e-07 | 1.874e-05 |
11 | ATPASE ACTIVITY | 7 | 427 | 1.182e-06 | 9.979e-05 |
12 | RIBONUCLEOTIDE BINDING | 12 | 1860 | 1.858e-06 | 0.0001439 |
13 | ATP DEPENDENT DNA HELICASE ACTIVITY | 3 | 34 | 1.277e-05 | 0.0009124 |
14 | RNA POLYMERASE ACTIVITY | 3 | 44 | 2.801e-05 | 0.001858 |
15 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 8 | 992 | 3.398e-05 | 0.002105 |
16 | SINGLE STRANDED DNA DEPENDENT ATPASE ACTIVITY | 2 | 13 | 0.0001356 | 0.007876 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | REPLICATION FORK | 13 | 62 | 1.232e-26 | 7.194e-24 |
2 | CHROMOSOME | 19 | 880 | 2.216e-20 | 6.383e-18 |
3 | REPLISOME | 9 | 29 | 3.279e-20 | 6.383e-18 |
4 | MCM COMPLEX | 7 | 11 | 1.151e-18 | 1.681e-16 |
5 | NUCLEAR REPLICATION FORK | 8 | 39 | 2.099e-16 | 2.451e-14 |
6 | NUCLEAR CHROMOSOME | 14 | 523 | 8.647e-16 | 8.417e-14 |
7 | PROTEIN DNA COMPLEX | 9 | 175 | 1.001e-12 | 8.348e-11 |
8 | NUCLEAR CHROMOSOME TELOMERIC REGION | 8 | 132 | 5.805e-12 | 4.238e-10 |
9 | CHROMOSOME TELOMERIC REGION | 8 | 162 | 3.033e-11 | 1.968e-09 |
10 | CHROMOSOMAL REGION | 8 | 330 | 8.529e-09 | 4.981e-07 |
11 | DNA POLYMERASE COMPLEX | 3 | 13 | 6.219e-07 | 3.302e-05 |
12 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 5 | 237 | 1.462e-05 | 0.0007113 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | Cell_cycle_hsa04110 | 10 | 124 | 4.476e-16 | 2.327e-14 |